Inadequacies in current therapies for atrial fibrillation have made new drug development
crucial. Conventional antiarrhythmic drugs increase the risk of ventricular proarrhythmia. In …

Purpose Rate and rhythm control are two well established treatment objectives for atrial
fibrillation (AF) patients. While symptom reduction is a primary treatment goal, therapeutic …

Introduction Management of atrial fibrillation (AF) is hampered by frequent recurrences after
restoration of sinus rhythm. Delayed interatrial conduction has been associated with the …

Atrial fibrillation (AF) is the most common sustained arrhythmia with a prevalence of up to
4% and an upwards trend due to demographic changes. It is associated with an increase in …

The relative efficacy of antiarrhythmic drugs (AADs) after electrical cardioversion are not well
established. This study aimed to investigate the efficacies of different AADs for maintaining …

La fibrilación auricular (FA) es la arritmia sostenida de mayor prevalencia en los servicios
de urgencias (SHU), que presentan una frecuentación elevada y creciente en España. La …

BACKGROUND: Vernakalant is a novel, relatively atrial-selective antiarrhythmic drug. This
analysis assessed the efficacy and safety of intravenous vernakalant for the rapid …

Background and objectives: To identify clinical, echocardiographic, and laboratory
parameters that affect the early recurrence of atrial fibrillation (AF) after restoring sinus …

Genotyping of ST2 and galectin-3 in atrial fibrillation (AF) is not well analyzed. The aim of
our study was to analyze the possible relationship between levels of sST2 and galectin-3 …

When should we measure biomarkers in patients with atrial fibrillation to predict recurrences?
When should we measure biomarkers in patients with atrial fibrillation to predict recurrences …